BlueWillow Biologics
  • Home
  • NanoVax Platform
    • Technology
    • Intranasal
    • Human Clinical Evidence
  • Company
    • About BlueWillow Biologics
    • Leadership Team
    • Contact
  • Press Room
    • News
    • Scientific Publications
  • Menu Menu
September 21, 2021
https://bluewillow.com/wp-content/uploads/2023/02/bw-logo-enfold.png 0 0 Ted https://bluewillow.com/wp-content/uploads/2023/02/bw-logo-enfold.png Ted2021-09-21 17:49:592025-09-25 08:07:22

News

  • H5 Influenza (Pandemic Flu) Clinical Trial Successful, Peer-Reivewed and Accepted for Publication
  • BlueWillow Biologics to Present Significant Progress on Its Novel Intranasal Vaccine Technology at World Vaccine Congress Europe
  • Dr. Shabaana Khader, University of Chicago, highlights promise of intranasal mucosal vaccine strategy for tuberculosis.

Contact

BlueWillow Biologics, Inc. 

2311 Green Rd. Suite A
Ann Arbor, MI 48105

734-302-4000
734-302-9150 fax

Link to: BlueWillow Biologics Announces Positive Interim Results from Phase 1 Trial of Intranasal Anthrax Vaccine Link to: BlueWillow Biologics Announces Positive Interim Results from Phase 1 Trial of Intranasal Anthrax Vaccine BlueWillow Biologics Announces Positive Interim Results from Phase 1 Trial of... Link to: BlueWillow Biologics Presents Positive Interim Anthrax Phase 1 Data to BARDA Link to: BlueWillow Biologics Presents Positive Interim Anthrax Phase 1 Data to BARDA BlueWillow Biologics Presents Positive Interim Anthrax Phase 1 Data to BARD...
Scroll to top Scroll to top Scroll to top